Your fact-checks will appear here
The use of ivermectin as a substitute for evidence-based cancer therapies and its associated harms.
Preclinical literature shows produces the most robust anticancer signals in (including triple‑negative), , , , (non‑small cell) and certain models, largely because it targets multiple survival and res...
Preclinical work identifies strongest anticancer signals for ivermectin in breast cancer, hematologic malignancies (notably leukemia), hepatocellular carcinoma, and several drug-resistant solid tumor ...
Clinical testing of ivermectin in cancer patients remains nascent: searches of the clinical literature and trial registries identify essentially one active early-phase trial combining ivermectin with ...
Patients who substitute ivermectin for evidence-based have suffered documented harms including (notably neurological effects at high doses and common gastrointestinal/skin reactions), dangerous drug–d...
Oncologists cite a cluster of regulatory and ethical concerns about repurposing antiparasitics like ivermectin for cancer: there is a stark gap between promising lab data and human evidence, known tox...